Results 61 to 70 of about 769,977 (264)

An [Imperfect] Case for Dyadic Research in Pediatric Psychosocial Oncology

Pediatric Blood &Cancer, EarlyView.
Stephanie M. Nanos, Lindsay A. Jibb, Gary Rodin   +2 more
wiley   +1 more source

Psychosocial Functioning After Pediatric Bone Sarcoma: Generic and Survivor‐Specific Outcomes in Adolescent and Young Adult Patients

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Pediatric bone sarcoma patients and survivors may experience psychosocial challenges related to childhood cancer after their intensive, body‐altering treatment. This cross‐sectional study aimed to evaluate generic and survivor‐specific psychosocial outcomes in a national cohort of pediatric bone sarcoma patients and survivors, and ...
Hinke van der Hoek, Heleen Maurice‐Stam, Laura R. Beek, Jennifer van Dijk, Marjolein E. M. Langemeijer, Relinde W. Slooff‐Lentink, Alied M. van der Aa‐van Delden, Anne Westerweel, Marloes van Gorp, Hendrik W. B. Schreuder, Lianne M. Haveman, W. Peter Bekkering, Leonie G. Tigelaar, Johannes H. M. Merks, Martha A. Grootenhuis   +14 more
wiley   +1 more source

Funding and services needed to achieve universal health coverage: applications of global, regional, and national estimates of utilisation of outpatient visits and inpatient admissions from 1990 to 2016, and unit costs from 1995 to 2016

The Lancet Public Health, 2019
Summary: Background: To inform plans to achieve universal health coverage (UHC), we estimated utilisation and unit cost of outpatient visits and inpatient admissions, did a decomposition analysis of utilisation, and estimated additional services and ...
Mark W Moses, MHS, Paola Pedroza, MPH, Ranju Baral, PhD, Sabina Bloom, BA, Jonathan Brown, MAIS, Abby Chapin, BA, Kelly Compton, BS, Erika Eldrenkamp, MPH, Nancy Fullman, MPH, John Everett Mumford, BA, Vishnu Nandakumar, BS, Katherine Rosettie, MPH, Nafis Sadat, MA, Tom Shonka, BA, Abraham Flaxman, PhD, Theo Vos, PhD, Chris J L Murray, DPhil, Marcia R Weaver, PhD   +17 more
doaj   +1 more source

On the Szegő Metric

Journal of Geometric Analysis, 2012
We introduce a new biholomorphically invariant metric based on Fefferman's invariant Szego kernel and investigate the relation of the new metric to the Bergman and Carathéodory metrics. A key tool is a new absolutely invariant function assembled from the Szego and Bergman kernels.
Barrett, David, Lee, Lina
openaire   +3 more sources

Ironic Medications: A Narrative‐Based Psycho‐Educational Intervention to Explore Patient–Provider Communication in Adolescents With Haematological Cancer

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Adolescents with haematological malignancies face significant emotional and relational challenges, often accompanied by difficulties in communicating their needs within the healthcare context. To address these issues, a narrative‐based psycho‐educational intervention based on the creation and prescription of Ironic Medications was ...
Marta Stoppa, Elena Pagani Bagliacca, Selena Russo, Giulia Rampoldi, Maria Grazia Strepparava, Adriana Cristina Balduzzi, Andrea Biondi, Marco Spinelli   +7 more
wiley   +1 more source

Incidence and Severity of Carboplatin‐Associated Hearing Loss in Children With Cancer Assessed by the SIOP Boston 2012 Ototoxicity Criteria

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Platinum‐based chemotherapy is known to cause severe and debilitating hearing loss, but unlike cisplatin, the true incidence of carboplatin‐induced hearing loss remains unclear. We evaluated functional hearing outcomes in children receiving carboplatin to determine the incidence and severity of ototoxicity. Procedure We identified a
Aniket Chawla, Sean Carter, Andrew Wood, Sandra Staffieri, Andrew Dodgshun, David D. Eisenstat, Michael Sullivan   +6 more
wiley   +1 more source

Association Between Dinutuximab Beta Exposure and Post‐End‐of‐Treatment Survival in Neuroblastoma: A Weighted Patient‐Level Analysis of Three Clinical Studies

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Objectives The association between exposure to dinutuximab beta (DB) and event‐free survival (EFS) or overall survival (OS) of neuroblastoma patients was assessed using data collected during three clinical trials (five cohorts). Methods A systematic review (March 2026) was conducted to identify relevant studies (prospective; registered DB ...
Przemysław Holko, Holger N. Lode, Alberto Garaventa, Carla Manzitti, Roberto Luksch, Dominique Valteau‐Couanet, Marion Gambart, John Anderson, Juliet Gray, Adela Canete, Lucas Moreno, Aleksandra Wieczorek, Cormac Owens, Shifra Ash, Isaac Yaniv, Genevieve Laureys, Hans Loibner, Katarzyna Śladowska, Ruth Ladenstein, Paweł Kawalec   +19 more
wiley   +1 more source

Disparities in telemedicine use and payment policies in the United States between 2019 and 2023

Communications Medicine
Background The COVID-19 pandemic induced an increase in telemedicine use in the American health care system. We assess disparities in telemedicine usage, the diseases and conditions it is used for, and the association of payment parity policies with ...
Anna D. Gage, Megan A. Knight, Corinne Bintz, Robert W. Aldridge, Olivia Angelino, Joseph L. Dieleman, M. Ashworth Dirac, Laura Dwyer-Lindgren, Simon I. Hay, Rafael Lozano, Ali H. Mokdad, Annie Haakenstad   +11 more
doaj   +1 more source

Long‐Term Outcomes of Patients With Relapsed/Refractory Neuroblastoma Treated on ANBL1221: A Report From the Children's Oncology Group

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Results of COG ANBL1221 changed treatment paradigms for patients with relapsed/refractory neuroblastoma. Chemoimmunotherapy with irinotecan/temozolomide/dinutuximab is now used as both bridge therapy following suboptimal response to induction and as treatment in first relapse.
Elizabeth Sokol, Arlene Naranjo, Lulu Chen, Rajen Mody, Steven G. DuBois, Rochelle Bagatell, Navin Pinto   +6 more
wiley   +1 more source

Global variation in bacterial strains that cause tuberculosis disease: a systematic review and meta-analysis

BMC Medicine, 2018
Background The host, microbial, and environmental factors that contribute to variation in tuberculosis (TB) disease are incompletely understood. Accumulating evidence suggests that one driver of geographic variation in TB disease is the local ecology of ...
Kirsten E Wiens, Lauren P Woyczynski, Jorge R Ledesma, Jennifer M Ross, Roberto Zenteno-Cuevas, Amador Goodridge, Irfan Ullah, Barun Mathema, Joel Fleury Djoba Siawaya, Molly H Biehl, Sarah E Ray, Natalia V Bhattacharjee, Nathaniel J Henry, Robert C Reiner, Hmwe H Kyu, Christopher J L Murray, Simon I Hay   +16 more
doaj   +1 more source